Actively Recruiting
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
Led by NewAmsterdam Pharma · Updated on 2025-10-20
100
Participants Needed
1
Research Sites
64 weeks
Total Duration
On this page
Sponsors
N
NewAmsterdam Pharma
Lead Sponsor
M
MB Clinical Research and Consulting LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are: Do Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants. Participants will: Take Obicetrapib or a placebo every day for 4 months Visit the clinic once every 8 weeks for checkups and tests Have their blood taken and their eyes checked to measure antioxidant levels
CONDITIONS
Official Title
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Visual acuity > 20/60 in both eyes with or without corrective lenses
You will not qualify if you...
- Type 2 diabetes
- Active liver disease
- Any clinically significant macular pathology
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Excellence Medical Research
Miami Gardens, Florida, United States, 33169
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here